Article
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.
Experimental hematology - 1 Sept 2020
Saberi Hosnijeh Fatemeh, van der Straten Lina, Kater Arnon P, van Oers Marinus H J, Posthuma Ward F M, Chamuleau Martine E D, Bellido Mar, Doorduijn Jeanette K, van Gelder Michel, Hoogendoorn Mels, de Boer Fransien, Te Raa G Doreen, Kerst J Martijn, Marijt Erik W A, Raymakers Reinier A P, Koene Harry R, Schaafsma Martijn R, Dobber Johan A, Tonino Sanne H, Kersting Sabina S, Langerak Anton W, Levin Mark-David
Abstract excerpt
Despite recent identification of several prognostic markers, there is still a need for new prognostic parameters able to predict clinical outcome in chronic lymphocytic leukemia (CLL) patients. Here, we aimed to validate the prognostic ability of known (proteomic) markers measured pretreatment and to search for new proteomic markers that might be related to treatment response in CLL. To this end, baseline serum...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.